Abeona Therapeutics (NASDAQ: ABEO) and Arbutus Biopharma Corporation (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Abeona Therapeutics and Arbutus Biopharma Corporation, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 0 7 0 3.00
Arbutus Biopharma Corporation 0 0 5 0 3.00

Abeona Therapeutics presently has a consensus target price of $19.71, suggesting a potential upside of 14.62%. Arbutus Biopharma Corporation has a consensus target price of $16.00, suggesting a potential upside of 220.00%. Given Arbutus Biopharma Corporation’s higher probable upside, analysts plainly believe Arbutus Biopharma Corporation is more favorable than Abeona Therapeutics.

Profitability

This table compares Abeona Therapeutics and Arbutus Biopharma Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics -2,746.38% -26.66% -23.94%
Arbutus Biopharma Corporation N/A -28.97% -21.71%

Insider and Institutional Ownership

38.2% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 67.1% of Arbutus Biopharma Corporation shares are held by institutional investors. 6.8% of Abeona Therapeutics shares are held by company insiders. Comparatively, 10.0% of Arbutus Biopharma Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abeona Therapeutics and Arbutus Biopharma Corporation’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics $842,999.00 821.99 -$23.80 million ($0.61) -28.20
Arbutus Biopharma Corporation $1.85 million 148.72 -$65.74 million ($5.13) -0.97

Abeona Therapeutics has higher revenue, but lower earnings than Arbutus Biopharma Corporation. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma Corporation, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Abeona Therapeutics has a beta of 2.26, suggesting that its stock price is 126% more volatile than the S&P 500. Comparatively, Arbutus Biopharma Corporation has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company’s lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.